Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial

All NewsAugust 27, 2025

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Amazon has a 12-piece nonstick carbon steel bakeware set with pans, sheets, and mitts for just $36

China October 2026 CPI +0.7% y/y (expected +0.8%, prior +0.9%)

Microsoft’s Oracle move raises new question for investors

Costco closes popular California store location after 37 years

Applebee’s and IHOP parent closes 208 restaurants